

Item 2.02. Results of Operations and Financial Condition.

On July 25, 2018, we issued a press release in which we reported our consolidated financial results for the three and six months ended June 30, 2018. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit | Description of Document |
|---------|-------------------------|
|---------|-------------------------|

| | |
|------|-------------------------------------------|
| 99.1 | <u>Press Release, dated July 25, 2018</u> |
|------|-------------------------------------------|

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)

Date: July 25, 2018 /s/ Michael J. LaCascia

Michael J. LaCascia
Senior Vice President and General Counsel